vs
Side-by-side financial comparison of Brightstar Lottery PLC (BRSL) and Organon & Co. (OGN). Click either name above to swap in a different company.
Brightstar Lottery PLC is the larger business by last-quarter revenue ($2.5B vs $1.5B, roughly 1.7× Organon & Co.). Organon & Co. runs the higher net margin — 10.0% vs 5.9%, a 4.1% gap on every dollar of revenue.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
BRSL vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $1.5B |
| Net Profit | $147.0M | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | 11.9% | — |
| Net Margin | 5.9% | 10.0% |
| Revenue YoY | — | -3.5% |
| Net Profit YoY | — | 67.8% |
| EPS (diluted) | $0.74 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.5B | ||
| Q4 25 | $2.5B | $1.5B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | $146.0M | ||
| Q4 25 | $147.0M | $-205.0M | ||
| Q3 25 | — | $160.0M | ||
| Q2 25 | — | $145.0M | ||
| Q1 25 | — | $87.0M | ||
| Q4 24 | — | $109.0M | ||
| Q3 24 | — | $359.0M | ||
| Q2 24 | — | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | 11.9% | -9.8% | ||
| Q3 25 | — | 15.2% | ||
| Q2 25 | — | 14.4% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 14.6% |
| Q1 26 | — | 10.0% | ||
| Q4 25 | 5.9% | -13.6% | ||
| Q3 25 | — | 10.0% | ||
| Q2 25 | — | 9.1% | ||
| Q1 25 | — | 5.8% | ||
| Q4 24 | — | 6.8% | ||
| Q3 24 | — | 22.7% | ||
| Q2 24 | — | 12.1% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | $0.74 | $-0.78 | ||
| Q3 25 | — | $0.61 | ||
| Q2 25 | — | $0.56 | ||
| Q1 25 | — | $0.33 | ||
| Q4 24 | — | $0.42 | ||
| Q3 24 | — | $1.38 | ||
| Q2 24 | — | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | — |
| Total DebtLower is stronger | $4.1B | — |
| Stockholders' EquityBook value | $875.0M | — |
| Total Assets | $9.2B | — |
| Debt / EquityLower = less leverage | 4.64× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $574.0M | ||
| Q3 25 | — | $672.0M | ||
| Q2 25 | — | $599.0M | ||
| Q1 25 | — | $547.0M | ||
| Q4 24 | — | $675.0M | ||
| Q3 24 | — | $763.0M | ||
| Q2 24 | — | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | $4.1B | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B |
| Q1 26 | — | — | ||
| Q4 25 | $875.0M | $752.0M | ||
| Q3 25 | — | $906.0M | ||
| Q2 25 | — | $733.0M | ||
| Q1 25 | — | $542.0M | ||
| Q4 24 | — | $472.0M | ||
| Q3 24 | — | $493.0M | ||
| Q2 24 | — | $144.0M |
| Q1 26 | — | — | ||
| Q4 25 | $9.2B | $12.9B | ||
| Q3 25 | — | $13.6B | ||
| Q2 25 | — | $13.5B | ||
| Q1 25 | — | $13.2B | ||
| Q4 24 | — | $13.1B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | 4.64× | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-99.0M | — |
| Free Cash FlowOCF − Capex | $-415.0M | — |
| FCF MarginFCF / Revenue | -16.5% | — |
| Capex IntensityCapex / Revenue | 12.6% | — |
| Cash ConversionOCF / Net Profit | -0.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-99.0M | $141.0M | ||
| Q3 25 | — | $264.0M | ||
| Q2 25 | — | $220.0M | ||
| Q1 25 | — | $75.0M | ||
| Q4 24 | — | $390.0M | ||
| Q3 24 | — | $141.0M | ||
| Q2 24 | — | $332.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-415.0M | $96.0M | ||
| Q3 25 | — | $218.0M | ||
| Q2 25 | — | $181.0M | ||
| Q1 25 | — | $43.0M | ||
| Q4 24 | — | $335.0M | ||
| Q3 24 | — | $99.0M | ||
| Q2 24 | — | $300.0M |
| Q1 26 | — | — | ||
| Q4 25 | -16.5% | 6.4% | ||
| Q3 25 | — | 13.6% | ||
| Q2 25 | — | 11.4% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | — | 6.3% | ||
| Q2 24 | — | 18.7% |
| Q1 26 | — | — | ||
| Q4 25 | 12.6% | 3.0% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | -0.67× | — | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BRSL
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
